Ultragenyx Pharmaceutical Inc 8-K, filed Apr 16, 2021
Ultragenyx Pharmaceutical Inc. (RARE)
About this 8-K
Ultragenyx Pharmaceutical Inc filed this 8-K on April 16, 2021, reporting on events of April 12, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On April 12, 2021, Clay B. Siegall, Ph.D., notified Ultragenyx Pharmaceutical Inc. (the “Company”) that he will not stand for re-election as a director of the Company upon the expiration of his current term at the Company’s 2021 annual meeting of stockholders (the “2021 Annual Meeting”). Dr. Siegall will continue to serve as a director of the Company until the 2021 Annual Meeting. Dr. Siegall’s decision to let his term expire and not to stand for re-election at the 2021 Annual Meeting is for personal reasons and not related to any disagreement with the Company on its operations, policies or practices.
(d) Exhibits
Exhibit No. |
Description |
104 |
The cover page from the Company’s Current Report on Form 8-K dated April 12, 2021 formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Ultragenyx Pharmaceutical Inc. |
|
|
|
|
Date: |
April 16, 2021 |
By: |
/s/ Mardi C. Dier |
|
|
|
Mardi C. Dier |